PL3045456T3 - Bicyklicznie podstawione uracyle i ich zastosowanie - Google Patents

Bicyklicznie podstawione uracyle i ich zastosowanie

Info

Publication number
PL3045456T3
PL3045456T3 PL16154186T PL16154186T PL3045456T3 PL 3045456 T3 PL3045456 T3 PL 3045456T3 PL 16154186 T PL16154186 T PL 16154186T PL 16154186 T PL16154186 T PL 16154186T PL 3045456 T3 PL3045456 T3 PL 3045456T3
Authority
PL
Poland
Prior art keywords
substituted uracils
bicyclic substituted
bicyclic
uracils
substituted
Prior art date
Application number
PL16154186T
Other languages
English (en)
Inventor
Chantal Fürstner
Jens Ackerstaff
Alexander Straub
Heinrich Meier
Hanna Tinel
Katja Zimmermann
Adrian Tersteegen
Dmitry Zubov
Reimund Kast
Jens Schamberger
Martina Schäfer
Kirsten Börngen
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of PL3045456T3 publication Critical patent/PL3045456T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
PL16154186T 2012-05-09 2013-05-03 Bicyklicznie podstawione uracyle i ich zastosowanie PL3045456T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167231 2012-05-09
EP16154186.7A EP3045456B1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung
EP13720407.9A EP2847190B1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung

Publications (1)

Publication Number Publication Date
PL3045456T3 true PL3045456T3 (pl) 2018-03-30

Family

ID=48289199

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16154186T PL3045456T3 (pl) 2012-05-09 2013-05-03 Bicyklicznie podstawione uracyle i ich zastosowanie
PL13720407.9T PL2847190T3 (pl) 2012-05-09 2013-05-03 Bicyklicznie podstawione uracyle i ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13720407.9T PL2847190T3 (pl) 2012-05-09 2013-05-03 Bicyklicznie podstawione uracyle i ich zastosowanie

Country Status (44)

Country Link
US (5) US9481672B2 (pl)
EP (2) EP3045456B1 (pl)
JP (2) JP6141414B2 (pl)
KR (1) KR102083281B1 (pl)
CN (2) CN106983751B (pl)
AP (1) AP2014008096A0 (pl)
AR (1) AR090994A1 (pl)
AU (2) AU2013258223B2 (pl)
BR (1) BR112014028086B1 (pl)
CA (1) CA2872906C (pl)
CL (1) CL2014003031A1 (pl)
CO (1) CO7131375A2 (pl)
CR (1) CR20140513A (pl)
CU (1) CU20140129A7 (pl)
CY (2) CY1118900T1 (pl)
DK (2) DK3045456T3 (pl)
DO (1) DOP2014000255A (pl)
EA (2) EA030383B9 (pl)
EC (1) ECSP14026138A (pl)
ES (2) ES2581537T3 (pl)
HK (1) HK1202873A1 (pl)
HR (2) HRP20160796T1 (pl)
HU (2) HUE029366T2 (pl)
IL (2) IL235438A (pl)
JO (1) JO3290B1 (pl)
LT (1) LT3045456T (pl)
MX (2) MX367599B (pl)
MY (1) MY181828A (pl)
NO (1) NO3045456T3 (pl)
NZ (1) NZ701700A (pl)
PE (1) PE20142301A1 (pl)
PH (1) PH12014502496B1 (pl)
PL (2) PL3045456T3 (pl)
PT (2) PT3045456T (pl)
RS (2) RS56784B1 (pl)
SA (1) SA113340533B1 (pl)
SG (1) SG10202003175QA (pl)
SI (2) SI3045456T1 (pl)
TN (1) TN2014000470A1 (pl)
TW (2) TWI579278B (pl)
UA (1) UA112897C2 (pl)
UY (1) UY34797A (pl)
WO (1) WO2013167495A1 (pl)
ZA (1) ZA201408146B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
EP3066095A1 (de) * 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte 1,2,4-triazin-3,5-dione und ihre verwendung als chymase hemmern
CN105658647B (zh) * 2013-11-08 2019-09-06 拜耳医药股份有限公司 化合物的盐
EP3066098A1 (de) 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
CN105873919A (zh) * 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
EP3338780A1 (de) * 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
EP3615031A1 (en) 2017-04-27 2020-03-04 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
SG11202011018PA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
WO2021000933A1 (zh) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
WO2022135514A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
CN114671878B (zh) * 2020-12-25 2023-08-04 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
TW202339706A (zh) * 2021-12-06 2023-10-16 美商普萊萃歐治療公司 含醯胺的lonp1抑制劑化合物、用途及方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2023194222A1 (en) * 2022-04-05 2023-10-12 Socpra Sciences Santé Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
WO2001017980A1 (fr) 1999-09-03 2001-03-15 Ajinomoto Co., Inc. Nouveaux procedes de preparation de derives d'oxazepine
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
JP2003017508A (ja) 2001-07-05 2003-01-17 Nec Corp 電界効果トランジスタ
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2003342265A (ja) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd トリアゾリジン誘導体およびその医薬用途
AU2003290735A1 (en) 2002-12-06 2004-06-30 Eli Lilly And Company Inhibitors of monoamine uptake
JP4387360B2 (ja) * 2003-08-22 2009-12-16 帝人ファーマ株式会社 キマーゼ阻害剤を有効成分として含有する薬剤
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ, エルエルシー 酵素モジュレータ及び治療
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
EP1968950A4 (en) 2005-12-19 2010-04-28 Genentech Inc PYRIMIDINKINASEINHIBITOREN
CA2642406A1 (en) 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
TWI394747B (zh) * 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en) 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
WO2008103277A2 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
KR20100075930A (ko) 2007-10-19 2010-07-05 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클-치환된 피페라지노-디하이드로티에노피리미딘
MX2010012067A (es) * 2008-05-05 2010-12-06 Merck Frosst Canada Ltd Derivados de 3,4-piperidina sustituida como inhibidores de la renina.
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

Also Published As

Publication number Publication date
NZ701700A (en) 2016-09-30
CN104395310A (zh) 2015-03-04
EA031222B1 (ru) 2018-12-28
BR112014028086A2 (pt) 2020-12-01
CR20140513A (es) 2014-12-02
HK1202873A1 (en) 2015-10-09
DK3045456T3 (da) 2018-01-29
CY1119840T1 (el) 2018-06-27
MY181828A (en) 2021-01-08
EP3045456B1 (de) 2017-10-25
AR090994A1 (es) 2014-12-30
EP2847190A1 (de) 2015-03-18
LT3045456T (lt) 2018-02-12
CN106983751A (zh) 2017-07-28
HUE029366T2 (en) 2017-02-28
CN106983751B (zh) 2020-01-07
SI2847190T1 (sl) 2016-08-31
KR102083281B1 (ko) 2020-05-29
EA201790032A1 (ru) 2017-05-31
KR20150016548A (ko) 2015-02-12
CA2872906C (en) 2020-08-04
US20200061063A1 (en) 2020-02-27
DOP2014000255A (es) 2015-02-27
US10300062B2 (en) 2019-05-28
JO3290B1 (ar) 2018-09-16
SI3045456T1 (en) 2018-03-30
HRP20160796T1 (hr) 2016-08-12
EP2847190B1 (de) 2016-04-06
US9949978B2 (en) 2018-04-24
ECSP14026138A (es) 2015-12-31
TWI635085B (zh) 2018-09-11
US9481672B2 (en) 2016-11-01
CN104395310B (zh) 2017-05-03
PH12014502496A1 (en) 2015-01-12
JP6367421B2 (ja) 2018-08-01
CU20140129A7 (es) 2015-02-26
MX357712B (es) 2018-07-20
RS54901B1 (sr) 2016-10-31
US20170020875A1 (en) 2017-01-26
TW201734007A (zh) 2017-10-01
TN2014000470A1 (en) 2016-03-30
SG10202003175QA (en) 2020-05-28
ES2657315T3 (es) 2018-03-02
AU2017265047A1 (en) 2017-12-14
US20150148340A1 (en) 2015-05-28
US20180256576A1 (en) 2018-09-13
EP3045456A1 (de) 2016-07-20
CO7131375A2 (es) 2014-12-01
PE20142301A1 (es) 2014-12-19
DK2847190T3 (en) 2016-07-25
JP2015516000A (ja) 2015-06-04
CA2872906A1 (en) 2013-11-14
MX2014013571A (es) 2014-12-08
MX367599B (es) 2019-08-28
US20170020876A1 (en) 2017-01-26
US9949977B2 (en) 2018-04-24
CL2014003031A1 (es) 2015-03-06
EA201492040A1 (ru) 2015-12-30
UY34797A (es) 2013-11-29
PT2847190T (pt) 2016-07-14
PT3045456T (pt) 2018-01-30
UA112897C2 (uk) 2016-11-10
PL2847190T3 (pl) 2016-12-30
JP2017160242A (ja) 2017-09-14
HRP20180125T1 (hr) 2018-02-23
IL235438A (en) 2017-08-31
EA030383B9 (ru) 2018-12-28
AU2013258223A1 (en) 2014-11-27
BR112014028086B1 (pt) 2021-09-21
SA113340533B1 (ar) 2015-10-12
ES2581537T3 (es) 2016-09-06
IL253950A0 (en) 2017-10-31
TW201406744A (zh) 2014-02-16
AU2017265047B2 (en) 2019-04-18
AP2014008096A0 (en) 2014-12-31
AU2013258223B2 (en) 2017-11-09
JP6141414B2 (ja) 2017-06-07
WO2013167495A1 (de) 2013-11-14
CY1118900T1 (el) 2018-01-10
ZA201408146B (en) 2017-01-25
TWI579278B (zh) 2017-04-21
IL253950B (en) 2019-07-31
EA030383B1 (ru) 2018-07-31
HUE035462T2 (en) 2018-05-02
RS56784B1 (sr) 2018-04-30
NO3045456T3 (pl) 2018-03-24
PH12014502496B1 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
IL253950A0 (en) Cyclic-converted uracils and their use
HK1203493A1 (en) Substituted azabicycles and use thereof
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1210949A1 (en) Combinations and uses thereof
SG11201403852UA (en) Fused pyrroledicarboxamides and their use as pharmaceuticals
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
EP2913325A4 (en) SUBSTITUTED PYRIMIDINE COMPOUND AND APPLICATIONS THEREOF
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
HK1201050A1 (en) Polypeptides and their use
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
GB201213726D0 (en) Novel compounds and their use
GB201222541D0 (en) Kiddibidet and pottibidet
GB201214749D0 (en) Compounds and their uses
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201205321D0 (en) Novel pyrimidines